Resistance to the four main classes of drugs (NRTIs, NNRTIs, PIs and INSTIs) affects a limited number of people with HIV.

However, these people with multidrug-resistant virus (MDR PLWH) are at high risk of clinical progression and virological failure.

Management of antiretroviral therapy in MDR PLWH is often complicated and may require a multidisciplinary approach to determine the best possible treatment.

The choice of an effective regimen in this population must necessarily take into account the pharmacological history, cumulative burden of drug resistance mutations and concomitant therapies of each MDR individual.

The Italian PRESTIGIO (Patients with HIV-1 infection with RESitence to Inverse Transcriptase, InteGrase and Viral Protease Inhibitors) Registry, which includes only MDR PLWH, aims to identify candidates for the use of new antiretroviral drugs and to optimise therapy in this vulnerable population.

The aim of this webinar is to bring together the centres of the Italian PRESTIGIO Registry to discuss complex clinical issues in a collegial manner, while providing a unique opportunity for discussion and updates in the field.